好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cancer Drug Repurposing for Treating Amyotrophic Lateral Sclerosis (ALS)
Neuromuscular and Clinical Neurophysiology (EMG)
S5 - Therapeutics in ALS and SMA (1:33 PM-1:44 PM)
004

The treatment of ALS is difficult because of multiple genetic causes and the interplay of genetics and environment as precipitating factors.  However, drugs to counteract the effect of genetic mutations have not yet been found.  The concept of repurposing existing drugs is attractive because much of the Phase I testing in humans has already been done by the manufacturer.  Certain tyrosine kinase inhibitors have been found to have neurotrophic activity.  We tested four drugs for their ability to decrease protein levels of one of the causative genes,Cu, Zn-superoxide dismutase (SOD1). Our rationale was that compounds that reduce expression of the toxic protein would be beneficial to slow onset and/or disease progression.


Test the tyrosine kinase inhibitor, Imatinib mesylate (Gleevec), a drug that is used to treat leukemia and other cancers for its effects on age-of-onset, progression, and end of life  in a mouse model of amyotrophic lateral sclerosis.


 Imatinib mesylate is a tyrosine kinase inhibitor targeting cAbl, PDGFRA, and others.. We tested it and related inhibitors (Dasitinib, Bosutinib, Nilotinib) in a cell-based assay. Only Imatinib decreased levels of soluble G93A-SOD1 with an IC50 of 110 nanomolar.   We then tested Imatinib in a pilot study (12-14 animals per group) in the G93A-SOD1 mouse.  Drug treatment was at a 2.5 mg/kg (IP), daily, beginning at age 60 (~30 days before disease symptoms).


 We found that Imatinib mesylate significantly delayed age-of-onset (p=0.003) and provided improvements in progression (p=0.03) and extending life (p=0.05) of the G93A-SOD1 mouse.


 Imatinib is orally active and penetrates the blood brain barrier making it a desirable clinical trial candidate for treating human neurodegenerative conditions such as ALS. The 2.5 mg/kg dose for the mouse is well within the dose range (200-800 mg/day) used for human cancer treatment
Authors/Disclosures
Thomas J. Lukas, PhD (Northwestern University)
PRESENTER
No disclosure on file
Teepu Siddique, MD, FAAN No disclosure on file